CDC/ACIP [to 5 November 2016]

CDC/ACIP [to 5 November 2016]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/

.
Press Release
FRIDAY, NOVEMBER 4, 2016
First cases of Candida auris reported in United States
Thirteen cases of Candida auris (C. auris), a serious and sometimes fatal fungal infection that is emerging globally, have been identified in the United States, according to the Centers for…

Media Advisory
WEDNESDAY, NOVEMBER 2, 2016
First annual One Health Day highlights link between people’s health and animals, environment
The first annual global One Health Day will be held Thursday, November 3, to raise awareness worldwide about the One Health concept, which recognizes that the health of people is…

.

MMWR Weekly November 4, 2016 / No. 43
:: Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons — Advisory Committee on Immunization Practices, 2016
At its June 2016 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of meningococcal conjugate vaccine (serogroups A, C, W, and Y; including MenACWY-D [Menactra, Sanofi Pasteur] or MenACWY-CRM [Menveo, GlaxoSmithKline]) for persons aged ≥2 months with human immunodeficiency virus (HIV) infection. ACIP has previously recommended routine vaccination of persons aged ≥2 months who have certain medical conditions that increase risk for meningococcal disease (1), including persons who have persistent (e.g., genetic) deficiencies in the complement pathway (e.g., C3, properdin, Factor D, Factor H, or C5–C9); persons receiving eculizumab (Soliris, Alexion Pharmaceuticals) for treatment of atypical hemolytic uremic syndrome or paroxysmal nocturnal hemoglobinuria (because the drug binds C5 and inhibits the terminal complement pathway); and persons with functional or anatomic asplenia (including persons with sickle cell disease). Routine vaccination with meningococcal conjugate vaccine is also recommended for all healthy adolescents in the United States (1). This report summarizes the evidence considered by ACIP in recommending vaccination for HIV-infected persons, and provides recommendations and guidance for use of meningococcal conjugate vaccines (serogroups A, C, W, and Y) among HIV-infected persons aged ≥2 months; the majority of meningococcal disease among HIV-infected persons is caused by these four serogroups…

:: Progress Toward Poliomyelitis Eradication — Afghanistan, January 2015–August 2016
:: Notes from the Field: Rift Valley Fever Response — Kabale District, Uganda, March 2016